Antipsychotic dosing strategies in acute schizophrenia

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 2, 1996, Pages 35-40

  Janicak, P G ^a   Davis, J M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antipsychotics; Clozapine; Dosing strategies; Neuroleptics; Plasma levels; Positron emission tomography; Risperidone; Sertindole

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SERTINDOLE; TRIFLUOPERAZINE;

CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0029975247     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199605002-00006     Document Type: Conference Paper

References (29)

1. Coryell W, Kelly M, Perry P, Miller DD (1990) Haloperidol plasma levels and acute clinical change in schizophrenia. J Clin Psychopharmacol 10:397-402.
2. Davis JM, Janicak PG (1995) A meta analysis of the clinical efficacy of risperidone versus standard neuroleptics. ACNP Scientific Abstracts Syllabus p 271.
3. Davis JM, Janicak PG, Preskorn SH, Ayd FJ (1994) Advances in the pharmacotherapy of psychotic disorders. In Update: Principles and Practice of Psychopharmacotherapy, vol 1, No 1. Edited by Janicak PG. Baltimore: Williams and Wilkins.
4. Fleischhacker WW, Hummer M, Kurz M, et al. (1994) Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 55 (suppl 9B):78-81.
5. Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis M (1984) Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 4: 133-137.
6. Haase HJ (1961) Extrapyramidal modification of fine movements: A 'conditio sine qua non' of the fundamental therapeutic action of neuroleptic drugs. In Systeme Extrapyramidal et Neuroleptique. Edited by Bordeleau JM. Montreal: Editions Psychiatriques; pp 329-353.
7. Janicak PG (1993) The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. J Clin Psychiatry 54 (suppl 9):35-41.
8. Janicak PG, Javaid JI, Sharma PR, Comaty JE, Peterson J, Davis JM (1989) Trifluoperazine plasma levels and clinical response. J Clin Psychopharmacol 9:340-346.
9. Janicak PG, Javaid JI, Davis JM (1993) Neuroleptic plasma levels: methodological issues, study design and clinical applicability. In The Clinical Use of Neuroleptic Plasma Levels. Edited by Marder S, Davis JM, Janicak PG. Washington, DC: American Psychiatric Press; pp 17-44.
10. Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Davis JM (1995) A double-blind randomized study of three haloperidol plasma levels for acute psychosis. In New Research and Program Abstracts American Psychiatric Association Meeting, Miami, FL, USA. New Research Abstract 459, 178-179.
11. Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
12. Marder SR (1992) Risperidone: clinical development: North American results. Clin Neuropharmacol 15 (suppl 1):92A-93A.
13. Mavroidis ML, Garver L (1985) Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacol Bull 21:62-65.
14. McEvoy JP, Hogarty G, Steingard S (1991) Optional dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48:739-745.
15. Müller-Spahn F (1992) Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel group study versus haloperidol. Clin Neuropharmacol 15 (suppl 1):90A-91A.
16. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110:365-367.
17. 2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology 110:265-272.
18. Palao DJ, Arauxo A, Brunet M, et al. (1994) Haloperidol: therapeutic window in schizophrenia. J Clin Psychopharmacol 14:303-310.
19. Perry PJ, Miller DD (1993) Clinical use of clozapine plasma concentrations. In Clinical Use of Neuroleptic Plasma Levels. Edited by Marder SR, Davis JM, Janicak PG. Washington, DC: American Psychiatric Press; pp 85-99.
20. Potkin SG, Shen Y, Zhou D, et al. (1985) Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull 21:59-61.
21. Potkin SG, Bera R, Gulasekaram B, et al. (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55 (suppl 9B):133-136.
22. Santos JL, Cabranes JA, Vasquez FF, Almoguera I, Ramos JA (1989) Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia. Biol Psychiatry 26: 381-388.
23. Smith RC (1987) Plasma haloperidol level and clinical response. Arch Gen Psychiatry 44:1110-1112.
24. Smith RC, Baumgartner R, Misra CH et al. (1984) Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia. Chemical versus radioreceptor plasma level assays. Arch Gen Psychiatry 41:1044-1049.
25. Van Putten T, Marder SR, May PRA, Poland RE, O'Brien RP (1985) Plasma levels of haloperidol and clinical response. Psychopharmacol Bull 21:69-72.
26. Van Putten T, Marder SR, Mintz J, Poland RE (1988) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Psychopharmacol Bull 24:172-175.
27. Volavka J, Cooper T, Czobor P, et al. (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49:354-361.
28. Volavka J, Cooper TB, Czobor P, Meisner M (1995) Plasma haloperidol levels and clinical effects in schizophrenia and schizo-affective disorder. Arch Gen Psychiatry 52:837-845.
29. Wolkin A, Brodie JD, Barouche F, et al. (1989) Dopamine receptor occupancy and haloperidol levels [letter]. Arch Gen Psychiatry 46:482-484.